Compare AbbVie Inc (ABBV) vs Appian Corp (APPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Appian Corp — how do they compare? AbbVie Inc trades at $253.86 (market cap $449.91B), while Appian Corp trades at $24.21 (market cap $1.81B). The key difference: AbbVie Inc is far larger — about 248.6× Appian Corp's market cap, and AbbVie Inc pays a 2.72% dividend while Appian Corp pays none. Which is the better fit depends on your goals.
| ABBV | APPN | |
|---|---|---|
Market Cap | $449.91B | $1.81B |
Sector | Health | Technology |
52-Week High | $261.07 | $45.64 |
52-Week Low | $184.85 | $18.72 |
Enterprise Value | $513.38B | $1.90B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Appian (APPN) trades at $24.68, up 1.15% with bullish technical signals from moving averages. The company shows strong revenue growth reaching $727M in 2025 and has beaten earnings estimates for three consecutive quarters. However, profitability remains minimal with a net margin of just 0.12% and negative shareholder equity of -$32.64M. Recent CEO stock sales and mixed analyst sentiment create uncertainty despite positive AI-driven business developments.
Appian presents a growth story with improving cash flow and AI positioning, but faces significant profitability challenges and negative equity. The stock trades near analyst consensus target of $26.20, suggesting limited upside. Key risks include sustained unprofitability and high debt levels, while opportunities lie in enterprise AI adoption and cloud revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →
